Miragen Therapeutics

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -24.00% and -9.56%, respectively, for the quarter ended December 2019.

Signal Genetics, Inc. (MGEN) Reports Q4 Loss, Lags Revenue Estimates

Is  (MGEN) Outperforming Other Medical Stocks This Year?

Has Signal Genetics (MGEN) Outpaced Other Medical Stocks This Year?

BOULDER, Colo., Feb.  07, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and warrants to purchase up to an aggregate of 7,500,000 shares of its common stock. Each share of common stock is being sold together with one-half  warrant, with each whole warrant exercisable   to purchase one whole share of common stock. Each share of common stock and accompanying one-half warrant is being sold  for a combined purchase price of $1.00, for a gross deal size of $15.0 million, not including any future proceeds from the exercise of the warrants and before deducting the underwriting discounts and commissions and offering expenses.  Each whole warrant will have an exercise price of $1.10 per share, will be exercisable immediately and will expire on the fifth anniversary of the date of issuance. The shares of common stock and warrants can only be purchased together but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on February 11, 2020, subject to customary closing conditions.

miRagen Announces Pricing of $15.0 Million Public Offering of Common Stock and Warrants to Purchase Common Stock

BOULDER, Colo., Feb.  06, 2020  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that it intends to offer for sale shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All of the common stock and warrants to purchase common stock are being offered by miRagen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

miRagen Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

Cobomarsen-treated adult T-cell leukemia/lymphoma (ATLL) patients with residual disease had a median survival time (MST) of 26 months compared with 7.4 months in a historical cohort - - -

miRagen Therapeutics Announces Positive Data for Cobomarsen in Adult T-Cell Leukemia/lymphoma Patients With Residual Disease

BOULDER, Colo., Dec.  11, 2019  (GLOBE NEWSWIRE) --  miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced a series of strategic changes across its business that are intended to reallocate its existing capital to deliver important milestones in 2020.  These changes  include a revised development strategy aimed at delivering data in 2020 from a modified  Phase 2 SOLAR clinical trial of cobomarsen in cutaneous T-cell lymphoma (CTCL), consulting with the U.S. Food and Drug Administration (FDA) to define a development path for cobomarsen in adult T-cell leukemia/lymphoma (ATLL), and focusing  future pipeline development efforts primarily on MRG-229, a novel second generation miR-29 mimic and potential treatment in patients with idiopathic pulmonary fibrosis (IPF). 

miRagen Announces Major Changes to Company’s Strategy

miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q3 2019 Results - Earnings Call Transcript

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -20.00% and -58.38%, respectively, for the quarter ended September 2019.

Signal Genetics, Inc. (MGEN) Reports Q3 Loss, Lags Revenue Estimates

Signal Genetics, Inc. (MGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

Earnings Preview: Signal Genetics, Inc. (MGEN) Q3 Earnings Expected to Decline

BOULDER, Colo., Oct.  28, 2019  (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, will present an overview of its novel second generation miR-29 mimics (MRG-229) at the DIA/FDA Oligonucleotide-Based Therapeutics Conference in Bethesda, Maryland, today.   In a separate session at the conference, miRagen will also review clinical development of its microRNA inhibitors. 

miRagen to Present at the DIA/FDA Oligonucleotide-Based Therapeutics Conference Today

Data included in an oral presentation at the 15th annual meeting of the Oligonucleotide Therapeutics Society

miRagen Announces New Clinical Data Showing MRG-110 Positively Impacted Tissue Repair and New Blood Vessel Growth

miRagen Therapeutics' (MGEN) CEO Bill Marshall on Q2 2019 Results - Earnings Call Transcript

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of 21.62% and 184.07%, respectively, for the quarter ended June 2019.

Signal Genetics, Inc. (MGEN) Reports Q2 Loss, Tops Revenue Estimates

Analysts Estimate Signal Genetics, Inc. (MGEN) to Report a Decline in Earnings: What to Look Out for

miRagen Therapeutics, Inc. (MGEN) CEO Bill Marshall on Q1 2019 Results - Earnings Call Transcript

Signal Genetics, Inc. (MGEN) delivered earnings and revenue surprises of -8.57% and -72.44%, respectively, for the quarter ended March 2019.

Signal Genetics, Inc. (MGEN) Reports Q1 Loss, Misses Revenue Estimates

Earnings Preview: Signal Genetics, Inc. (MGEN) Q1 Earnings Expected to Decline

miRagen Therapeutics, Inc. (MGEN) CEO William Marshall on Q4 2018 Results - Earnings Call Transcript

News for Miragen Therapeutics Stock (MGEN)